BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15287862)

  • 1. Increased levels of tissue inhibitor of metalloproteinase-1 in human hepatocellular carcinoma.
    Matsumoto E; Nakatsukasa H; Nouso K; Kobayashi Y; Nakamura S; Suzuki M; Takuma Y; Tanaka H; Fujikawa T; Shiratori Y
    Liver Int; 2004 Aug; 24(4):379-83. PubMed ID: 15287862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas.
    Nakatsukasa H; Ashida K; Higashi T; Ohguchi S; Tsuboi S; Hino N; Nouso K; Urabe Y; Kinugasa N; Yoshida K; Uematsu S; Ishizaki M; Kobayashi Y; Tsuji T
    Hepatology; 1996 Jul; 24(1):82-8. PubMed ID: 8707287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
    Matsunaga Y; Koda M; Murawaki Y
    Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells.
    Kim JR; Kim CH
    Int J Biochem Cell Biol; 2004 Nov; 36(11):2293-306. PubMed ID: 15313474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of TIMP-1 mediated by recombinant adenovirus in hepatocellular carcinoma cells inhibits proliferation and invasion in vitro.
    Xia D; Yan LN; Xie JG; Tong Y; Yan ML; Wang XP; Zhang MM; Zhao LY
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):409-15. PubMed ID: 16911941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma.
    Altadill A; Rodríguez M; González LO; Junquera S; Corte MD; González-Dieguez ML; Linares A; Barbón E; Fresno-Forcelledo M; Rodrigo L; Vizoso FJ
    Dig Liver Dis; 2009 Oct; 41(10):740-8. PubMed ID: 19372066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q; Liang LJ; Peng BG; Zhen YY
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma.
    Yao DF; Wu XH; Zhu Y; Shi GS; Dong ZZ; Yao DB; Wu W; Qiu LW; Meng XY
    Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):220-6. PubMed ID: 15908319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X-linked inhibitor of apoptosis (XIAP) and XIAP-associated factor-1 expressions and their relationship to apoptosis in human hepatocellular carcinoma and non-cancerous liver tissues.
    Sakemi R; Yano H; Ogasawara S; Akiba J; Nakashima O; Fukahori S; Sata M; Kojiro M
    Oncol Rep; 2007 Jul; 18(1):65-70. PubMed ID: 17549347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
    Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
    Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis.
    Cucchetti A; Vivarelli M; Piscaglia F; Nardo B; Montalti R; Grazi GL; Ravaioli M; La Barba G; Cavallari A; Bolondi L; Pinna AD
    J Hepatol; 2005 Aug; 43(2):310-6. PubMed ID: 15970351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma.
    Lee YC; Pan HW; Peng SY; Lai PL; Kuo WS; Ou YH; Hsu HC
    Eur J Cancer; 2007 Mar; 43(4):736-44. PubMed ID: 17267202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma.
    Akiba J; Ogasawara S; Kawahara A; Nishida N; Sanada S; Moriya F; Kuwano M; Nakashima O; Yano H
    Oncol Rep; 2008 Dec; 20(6):1329-35. PubMed ID: 19020710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
    Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
    Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of MT3-MMP in hepatocellular carcinoma correlates with capsular invasion.
    Arai I; Nagano H; Kondo M; Yamamoto H; Hiraoka N; Sugita Y; Ota H; Yoshioka S; Nakamura M; Wada H; Damdinsuren B; Kato H; Marubashi S; Miyamoto A; Takeda Y; Dono K; Umeshita K; Nakamori S; Wakasa K; Sakon M; Monden M
    Hepatogastroenterology; 2007; 54(73):167-71. PubMed ID: 17419254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of des-gamma-carboxy prothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma.
    Yuan LW; Tang W; Kokudo N; Sugawara Y; Karako H; Hasegawa K; Aoki T; Kyoden Y; Deli G; Li YG; Makuuchi M
    Oncol Rep; 2004 Aug; 12(2):269-73. PubMed ID: 15254687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.
    Shimoda M; Ghobrial RM; Carmody IC; Anselmo DM; Farmer DG; Yersiz H; Chen P; Dawson S; Durazo F; Han S; Goldstein LI; Saab S; Hiatt J; Busuttil RW
    Liver Transpl; 2004 Dec; 10(12):1478-86. PubMed ID: 15558585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients.
    El Tayebi HM; Salah W; El Sayed IH; Salam EM; Zekri AR; Zayed N; Salem ES; Esmat G; Abdelaziz AI
    Biomarkers; 2011 Jun; 16(4):346-54. PubMed ID: 21506705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.